It’s been an exciting year for new drug approvals in 2017. Many of these new medicines address significant and meaningful needs, or offer additional therapeutic choices for patients and physicians. But there appears to be a surprising lack of novel, first-in-class mechanisms in this year's cohort.
from Forbes Real Time https://www.forbes.com/sites/brucebooth/2017/11/30/in-search-of-novelty-2017s-new-fda-drug-approvals/
via IFTTT
No comments:
Post a Comment